Based on the phase I results, we conducted a multi-institutional phase II trial of lapatinib and vinorelbine in patients with HER2-positive advanced breast cancer who had received up to one prior chemotherapeutic regimen for metastatic disease. The gene discussed is ERBB2; the disease is breast carcinoma.